Celecoxib as Adjuvant Therapy to Chemotherapy in Patients With Metastatic Colorectal Cancer
Launched by SHERIEF ABD-ELSALAM · Aug 22, 2018
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a medication called celecoxib when added to standard chemotherapy for patients with metastatic colorectal cancer, which means the cancer has spread beyond the colon. The goal is to see if celecoxib can help improve the effectiveness of the chemotherapy in treating this advanced stage of cancer.
To participate in this trial, patients should be between 65 and 75 years old and have advanced colorectal cancer. However, those with certain conditions, like brain metastases (cancer that has spread to the brain), other types of cancer, or specific infections, will not be eligible. If you join the study, you can expect to receive the chemotherapy treatment along with celecoxib, and the researchers will monitor your health and response to the treatment closely. This trial is currently recruiting participants, so those interested can reach out for more information.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • advanced colorectal cancer
- Exclusion Criteria:
- • cerebral metastases
- • other malignancy
- • H pylori infection
- • thromboembolism
About Sherief Abd Elsalam
Sherief Abd-elsalam is a dedicated clinical trial sponsor with extensive expertise in advancing medical research and innovation. Committed to improving patient outcomes, Abd-elsalam oversees the design, implementation, and management of clinical trials across various therapeutic areas. With a strong focus on regulatory compliance and ethical standards, he fosters collaboration between research institutions, healthcare professionals, and regulatory bodies to ensure the successful progression of trials. Abd-elsalam's leadership is characterized by a commitment to scientific integrity and a passion for translating research findings into actionable healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tanta, Elgharbia, Egypt
Patients applied
Trial Officials
Tarek M Mostafa, Prof
Principal Investigator
Clinical pharmacy Department- Tanta University
Mohamed Alm El-din, prof
Study Director
Clinical Oncology - Tanta University
Amira Roushdy, Msc
Study Director
Clinical pharmacy Department- Tanta University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials